Heart attack and acute coronary syndrome
Heart Attack Symptoms
Common signs and symptoms of heart attack include:
Immediate Treatment of a Heart Attack Patient
If you think you are having a heart attack, call 9-1-1 right away and wait for an ambulance. DO NOT attempt to drive yourself to the hospital. After you call 9-1-1, chew an adult-size (325 mg) non-coated aspirin. Be sure to tell the paramedics so an additional aspirin dose is not given.
For a particular type of heart attack called ST-elevation myocardial infarction or STEMI, which is diagnosed by electrocardiography (ECG or EKG), guidelines recommend:
Secondary Prevention of Heart Attack
Secondary prevention measures are essential to help prevent another heart attack. DO NOT leave the hospital without discussing these secondary prevention steps with your doctor:
Aspirin for Heart Attack Prevention
The American Heart Association recommends daily low-dose aspirin for:
New Drug Approval
In 2013, the FDA approved vorapaxar (Zontivity) to reduce the risk of heart attack, stroke, or death from heart disease in patients who have had a heart attack. Vorapaxar is a new type of antiplatelet drug. Like all anti-clotting drugs, vorapaxar increases the risk for bleeding. Patients who have had a stroke should not use this drug because the risk of bleeding is too high.
The heart is the body's hardest working organ. Throughout life it continuously pumps blood enriched with oxygen and vital nutrients through a network of arteries to all tissues of the body. To perform this strenuous task, the heart muscle itself needs a plentiful supply of oxygen-rich blood, provided through a network of coronary arteries. These arteries carry oxygen-rich blood to the heart's muscular walls (the myocardium).
A heart attack (myocardial infarction) occurs when blood flow to the heart muscle is blocked, and tissue death occurs from loss of oxygen, severely damaging a portion of the heart.
Atherosclerosis is the hardening and narrowing of the arteries caused by the build-up of plaque inside the arteries. (Plaque is the sticky substance made up of fat, cholesterol, calcium, and other substances found in the blood.) Cardiovascular diseases caused by atherosclerosis include coronary artery disease, heart attack, peripheral artery disease, and stroke.
Coronary artery disease causes nearly all heart attacks. Coronary artery disease is the end result of a complex process called atherosclerosis (commonly called "hardening of the arteries"). This causes blockage of arteries (ischemia) and prevents oxygen-rich blood from reaching the heart.
Heart attack (myocardial infarction) is among the most serious outcome of atherosclerosis. A heart attack can result in several ways from atherosclerosis:
Angina, the primary symptom of coronary artery disease, is typically experienced as chest pain. There are two kinds of angina:
Acute Coronary Syndromes (ACS)
Acute coronary syndromes (ACS) are a group of severe and sudden heart conditions that need urgent/emergent and aggressive treatment. ACS include:
Patients diagnosed with an ACS are at risk for complications. Doctors use a patient's medical history, various tests, and the presence of certain factors to help predict which ACS patients are most at risk for developing a more serious condition. The severity of chest pain itself does not necessarily indicate the actual amount of damage to the heart.
The risk factors for heart attack are the same as those for coronary artery disease (heart disease). They include:
The risks for coronary artery disease increase with age. About 85% of people who die from heart disease are over the age of 65. For men, the average age of a first heart attack is 66 years.
Men have a greater risk for coronary artery disease overall, and are more likely to have heart attacks earlier in life than women. However, women's risk for heart disease increases after menopause (typically 10 years later than men), and cardiovascular diseases are the most common cause of death and disability in women in the US.
Genetic Factors and Family History
Certain genetic factors increase the likelihood of developing important risk factors, such as diabetes, elevated cholesterol, and high blood pressure.
Race and Ethnicity
African Americans have the highest risk of heart disease in part due to their high rates of severe high blood pressure as well as diabetes and obesity.
Obesity and Metabolic Syndrome
Excess body fat, especially around the waist, can increase the risk for heart disease. Obesity also increases the risk for other conditions (such as high blood pressure and diabetes) that are associated with heart disease. Obesity is particularly hazardous when it is part of the metabolic syndrome, a pre-diabetic condition that is significantly associated with heart disease. This syndrome is diagnosed when three of the following are present:
There are many ways to control your weight.
Unhealthy Cholesterol Levels
Low-density lipoprotein (LDL) cholesterol is the "bad" cholesterol responsible for many heart problems. Triglycerides are another type of lipid (fat molecule) that can be bad for the heart. High-density lipoprotein (HDL) cholesterol is the "good" cholesterol that helps protect against heart disease. Doctors test for a "total cholesterol" profile that includes measurements for LDL, HDL, and triglycerides. The ratio of these lipids can affect heart disease risk. New guidelines for cholesterol treatment focus on reducing a patient's overall risk for or from cardiovascular disease, rather than aiming for a target cholesterol number.
High Blood Pressure
High blood pressure (hypertension) is associated with coronary artery disease and heart attack. For an adult, a normal blood pressure reading is below 120/80 mm Hg. High blood pressure is generally considered to be a blood pressure reading greater than or equal to 140 mm Hg (systolic) or greater than or equal to 90 mm Hg (diastolic). Blood pressure readings in the prehypertension category (120 to 139 systolic or 80 to 89 diastolic) indicate an increased risk for developing hypertension.
Diabetes, especially for people whose blood sugar levels are not well controlled, significantly increases the risk of developing heart disease. In fact, heart disease and stroke are the leading causes of death in people with diabetes. People with diabetes, both type 1 (so-called "juvenile") and type 2 (so-called "adult onset"), are also at risk for high blood pressure and unhealthy cholesterol levels, blood clotting problems, kidney disease, and impaired nerve function, all of which can damage the heart.
Exercise has a number of effects that benefit the heart and circulation, including improving cholesterol levels and blood pressure and maintaining weight control. People who are sedentary are almost twice as likely to suffer heart attacks as are people who exercise regularly.
Smoking is the most important lifestyle risk factor for heart disease. Smoking can cause elevated blood pressure, worsen lipids, and make platelets very sticky, raising the risk of clots. Although heavy cigarette smokers are at greatest risk, people who smoke as few as 3 cigarettes a day are at higher risk for blood vessel abnormalities that endanger the heart. Regular exposure to passive smoke also increases the risk of heart disease in nonsmokers.
Moderate alcohol consumption (one or two glasses a day) can help boost HDL (good) cholesterol levels. Alcohol may also prevent blood clots and inflammation. By contrast, heavy drinking harms the heart. In fact, heart disease is the leading cause of death in alcoholics.
Diet plays an important role in protecting the heart, especially by reducing dietary sources of trans fats, saturated fats, and cholesterol and restricting salt intake that contributes to high blood pressure.
NSAIDs and COX-2 Inhibitors
All nonsteroidal anti-inflammatory drugs (NSAIDs) -- with the exception of aspirin -- carry heart risks. NSAIDs and COX-2 inhibitors may increase the risk for death in patients who have experienced a heart attack. The risk is greatest at higher dosages. But some research suggests that even low doses of NSAIDs taken for short periods of time are not safe after a heart attack.
NSAIDs include nonprescription drugs like ibuprofen (Advil, Motrin, generic) and prescription drugs like diclofenac (Cataflam, Voltaren, generic). Celecoxib (Celebrex) is currently the only COX-2 inhibitor that is available in the US. It has been linked to cardiovascular risks, such as heart attack and stroke. Patients who have had heart attacks should talk to their doctors before taking any of these drugs.
The American Heart Association recommends that patients who have, or who are at risk for, heart disease first try non-drug methods of pain relief (such as physical therapy, exercise, weight loss to reduce stress on joints, and heat or cold therapy). If these methods don't work, patients should take the lowest effective and safe dose of acetaminophen (Tylenol, generic) or aspirin before using an NSAID. The COX-2 inhibitor celecoxib (Celebrex) should be a last resort.
Heart attacks may be rapidly fatal, evolve into a chronic disabling condition, or lead to full recovery. The long-term prognosis for both length and quality of life after a heart attack depends on its severity, the amount of damage sustained by the heart muscle, the preventive measures taken afterward, and the prior health status of the patient.
Patients who have had a heart attack have a higher risk of a second heart attack. Although no tests can absolutely predict whether another heart attack will occur, patients can reduce their risk of having another heart attack by healthy lifestyle changes and adherence to medical treatments.
Heart attack also increases the risk for other heart problems, including heart failure, abnormal heart rhythms, heart valve damage, and stroke.
Higher Risk Individuals
A heart attack is always more serious in certain people, including:
Women are more likely to die from a heart attack than men. The gender difference is greatest for younger patients.
Factors Occurring at the Time of a Heart Attack That Increase Severity
The presence of other conditions during a heart attack can contribute to a poorer outlook:
Heart Attack Symptoms
Heart attack symptoms can vary. They may come on suddenly and severely or may progress slowly, beginning with mild pain. Although chest pain is the classic symptom associated with heart attack, a third of patients DO NOT experience this symptom.
Symptoms can vary between men and women. Women, older people and diabetes are less likely than men to have chest pain. But they are more likely to experience shortness of breath, nausea or vomiting, or jaw and back pain.
Common signs and symptom of heart attack include:
Symptoms That are Less Likely to Indicate Heart Attack
The following symptoms are less likely to be due to heart attack:
However, the presence of these symptoms does not necessarily rule out a serious heart event.
Some people with severe coronary artery disease DO NOT have angina pain. This condition is known as silent ischemia. This is a dangerous condition because patients have no warning signs of heart disease.
What to do When Symptoms Occur
If you are having chest pain or other symptoms that may indicate a heart attack, you should:
When a patient comes to the hospital with chest pain, the following diagnostic steps are usually taken to determine any heart problems and, if present, their severity:
An electrocardiogram (ECG or EKG) measures and records the electrical activity of the heart. The waves measured by the ECG correspond to the contraction and relaxation pattern of the different parts of the heart. Specific waves seen on an ECG are named with letters:
Doctors also use a term called the P-R interval, which is the time it takes for an electrical impulse to travel from the atria to the ventricles.
The most important wave patterns in diagnosing and determining treatment for a heart attack are called ST elevations and Q waves.
Elevated ST Segments: Heart Attack
Elevated ST segments are strong indicators of a heart attack in patients with compatible symptoms and other indicators. They suggest that an artery to the heart is blocked and that the full thickness of the heart muscle is damaged. The kind of heart attack associated with these findings is referred to as either a Q-wave myocardial infarction or a STEMI.
However, ST-segment elevations DO NOT always mean the patient has a heart attack. For example, an inflammation in the sack around the heart (pericarditis) is another cause of ST-segment elevation.
Non-Elevated ST Segments: Stable Angina, Unstable Angina, and Non-ST Segment Elevation Myocardial Infarction
A depressed or horizontal ST segment may suggest some degree of coronary artery blockage and the presence of heart disease, even if there is no angina present. It occurs in about half of patients with other signs of a heart event. This finding, however, is not very specific, and can occur without heart problems. In such cases, laboratory tests are needed to determine the extent, if any, of heart damage.
In general, one of the following conditions may be present:
An echocardiogram is a noninvasive test that uses ultrasound images of the heart. Your doctor can see whether a part of your heart muscle has been damaged and is not moving normally. An echocardiogram may also be used as part of an exercise stress test, to detect the location and extent of heart muscle and other areas which may be "at risk," at the time of discharge or soon after you leave the hospital after a heart attack.
Radionuclide Imaging (Thallium Stress Test)
Radionuclide procedures use imaging techniques and computer analyses to plot and detect the passage of radioactive tracers through the region of the heart. Such tracing elements are typically given intravenously. Radionuclide imaging is useful for diagnosing and determining:
The procedure is noninvasive. It is a reliable measure of severe heart events and can help identify if damage has occurred from a heart attack. A radioactive isotope such as thallium (or technetium) is injected into the patient's vein. The radioactive isotope attaches to red blood cells and passes through the heart in the circulating blood. The isotope can then be traced through the heart using special cameras called scanners.
The patient is imaged while resting, then imaged again after an exercise stress test. Sometimes scans are done to evaluate if damaged heart muscle may recover if blood flow is improved. For these tests images are obtained after a significant delay (up to 24 hours).This is called a myocardial "viability study."
Angiography is an invasive test. It is used when doctors require a detailed "road map" of coronary artery blockages. In the procedure:
When heart cells become damaged, they release different enzymes and other molecules into the bloodstream. Elevated levels of such markers of heart damage in the blood or urine may help diagnose a heart attack in patients with severe chest pain, and help determine treatment. Tests for these markers are often performed in the emergency room or hospital when a heart attack is suspected. Some markers include: The proteins cardiac troponin T and I are released when the heart muscle is damaged. Troponins are the most specific biomarkers for diagnosing heart attack.
The proteins cardiac troponin T and I are released when the heart muscle is damaged. Troponins are the most specific biomarkers for diagnosing heart attack. Cardiac troponin levels are normally so low they cannot be detected with most blood tests. Having normal troponin levels 12 hours after chest pain has started means a heart attack is unlikely, but does not rule out unstable angina.
Even a slight increase in the troponin level will often mean there has been some damage to the heart. Very high levels of troponin are a sign that a heart attack has occurred. Most patients who have had a heart attack have increased troponin levels within 6 hours. After 12 hours, almost everyone who has had a heart attack will have raised levels. Troponin levels may remain high for 1 to 2 weeks after a heart attack.
Increased troponin levels may also be due to:
Creatine kinase myocardial band (CK-MB)
CK-MB had been a standard marker for many years, but is not as accurate as troponin levels, because there are more conditions where elevated levels can appear in people without heart injury.
Heart attack is usually treated by:
Immediate Treatments to Support the Patient
Oxygen is almost always administered right away, usually through a tube that enters through the nose.
The patient is given aspirin if one was not taken at home.
Medications for Relieving Symptoms
Opening the Arteries: Emergency Angioplasty or Thrombolytic Drugs
With a STEMI heart attack, a clot that has formed in a coronary artery that supplies oxygen to the heart muscle blocks it completely. Opening a clotted artery as quickly as possible is the best approach to improving survival and limiting the amount of heart muscle that is permanently damaged. Guidelines recommend that communities have emergency systems in place to ensure that heart attack patients are directed to appropriate medical centers equipped to treat them as quickly as possible.
The standard medical and surgical solutions for opening arteries are:
Thrombolytic, also called clot-busting or fibrinolytic, drugs are recommended as alternatives to angioplasty. These drugs dissolve the clot, or thrombus, responsible for causing artery blockage and heart-muscle tissue death.
Generally speaking, thrombolysis is considered a good option for patients with full-thickness (STEMI) heart attacks when symptoms have been present for fewer than 12 hours. Ideally, these drugs should be given within 30 minutes of arriving at the hospital if angioplasty is not a viable option. Other situations where a clot-busting drug may be used include:
Thrombolytics should be avoided or used with great caution in the following patients:
The standard thrombolytic drugs are recombinant tissue plasminogen activators or rt-PAs. They include alteplase (Activase) and reteplase (Retavase) as well as a newer drug tenecteplase (TNKase). Other types of drugs, such as a combination of an antiplatelet and anticoagulant, may also be given to prevent the clot from growing larger or any new clots from forming.
The sooner that thrombolytic drugs are given after a heart attack, the better. The benefits of thrombolytics are highest within the first 3 hours. They can still help if given within 12 hours of a heart attack.
Hemorrhagic stroke, usually occurring during the first day, is the most serious complication of thrombolytic therapy, but fortunately it is rare.
Revascularization Procedures: Angioplasty and Bypass Surgery
PCI, also called angioplasty (usually done with stent placement), and CABG surgery are the standard procedures for dealing with narrowed or blocked arteries. These procedures help restore blood flow (perfusion). They are known as revascularization procedures:
Most patients who meet the criteria for either thrombolytic drugs or angioplasty do better with angioplasty (although not all hospitals are equipped to do this procedure).
Angioplasty/PCI involves procedures such as percutaneous transluminal coronary angioplasty (PTCA) that help open the blocked artery. A typical angioplasty procedure involves the following steps:
Complications occur in about 5% to 10% of patients (most complications occur within the first day). Best results occur in hospital settings with experienced teams and backup. Women who have angioplasty after a heart attack have a higher risk of death than men.
Reclosure and Blockage During or After Angioplasty
Sudden narrowing or reclosure of the artery (stent thrombosis) can occur during or shortly after angioplasty, or even as long as a year or more after the procedure. When it occurs, the symptoms and signs are those of a STEMI and usually require a repeat angioplasty procedure (a new stent is usually inserted within the prior one). This is a very serious and sometimes deadly occurrence.
Slow narrowing of a stent, which occurs because of new tissue growth in the wall of the artery and stent, is called "in-stent restenosis." With this condition, symptoms usually occur more gradually.
Drug-eluting stents, which are coated with everolimus, sirolimus, or paclitaxel, can help prevent restenosis, and reduce repeat procedures on the same area, although they do have a slightly higher risk of stent thrombosis.
Although all patients are prescribed aspirin and another antiplatelet medication (such as clopidogrel) for at least a year after a heart attack, those who have a stent placed must take both for at least a month for a bare metal stent and at least a year for a drug-eluting stent, unless directed by their cardiologist. This greatly reduces the risk of the stent closing suddenly. Clopidogrel, like aspirin, helps to prevent blood platelets from clumping together.
Prasugrel (Effient) is a newer antiplatelet drug that may be used as an alternative to clopidogrel for select patients with ACS who are undergoing angioplasty. It should not be used by patients who have had a previous stroke or transient ischemic attack. Another option for patients is the new antiplatelet drug ticagrelor (Brilinta). Ticlopidine (Ticlid) is an older antiplatelet drug that is less commonly used. Like clopidogrel, these antiplatelets are taken in combination with aspirin.
If for some reason patients cannot take a second antiplatelet along with aspirin after angioplasty and stenting for longer than 4 to 6 weeks, they should receive a bare metal stent instead of a drug-eluting stent.
Coronary Artery Bypass Graft Surgery (CABG)
CABG surgery is the alternative procedure to angioplasty for opening blocked arteries, particularly for patients who have two or more blocked arteries. However, it is a very invasive procedure and requires a longer hospitalization and recovery period. In a CABG procedure:
Treatment for Patients in Shock or With Heart Failure
Severely ill patients, particularly those with heart failure or who are in cardiogenic shock, will be monitored closely and stabilized. Oxygen is administered, and fluids are given or replaced when it is appropriate to either increase or reduce blood pressure. Such patients may be given dopamine, dobutamine, or other powerful medications (or a combination). Other treatments depend on the specific condition.
Intravenous furosemide may be administered to remove excess fluid from the lungs and other areas. Patients may also be given nitrates, and ACE inhibitors, unless they have a severe drop in blood pressure or other conditions that preclude them. Clot-busting drugs or angioplasty may be appropriate.
Cardiogenic shock is a dangerous condition that includes a drop in blood pressure and other abnormalities. Using a special long catheter, a procedure called intra-aortic balloon counterpulsation (IABP) can help patients with cardiogenic shock around the time of revascularization. IABP involves inserting a catheter containing a long balloon, which is inflated and deflated within the artery to boost blood pressure and decrease the load on the heart. More powerful left ventricular assist devices that can provide more support may also be considered.
Treatment of Arrhythmias
An arrhythmia is a deviation from the heart's normal beating pattern caused when the heart muscle is deprived of oxygen.
Several different arrhythmias may occur during or after a heart attack. Some are less severe, but some can be deadly. Sometimes arrhythmias can cause the heart to beat very slowly and a pacemaker may be needed. Other arrhythmias may cause fast heart rhythms that can lead to sudden death.
A lethal rhythm abnormality, in which the ventricles of the heart beat so rapidly that they DO NOT actually contract but quiver ineffectually. The pumping action necessary to keep blood circulating is lost.
Preventing Ventricular Fibrillation.
People who develop ventricular fibrillation DO NOT always experience warning arrhythmias, and to date, there are no effective drugs for preventing arrhythmias during a heart attack. Preventive strategies include:
Treating Ventricular Fibrillation
Treatment strategies for ventricular fibrillation include:
Managing Other Arrhythmias
People with an arrhythmia called atrial fibrillation have a higher risk for stroke after a heart attack and are usually treated with anticoagulants such as warfarin (Coumadin, generic), dabigatran (Pradaxa), rivaroxaban (Xarelto), or apixaban (Eliquis). Other rhythm disturbances called bradyarrhythmias (very slow rhythm disturbances) frequently develop in association with a heart attack and may be treated with atropine or pacemakers.
Aspirin and Other Anti-Clotting Drugs
Anti-clotting drugs that inhibit or break up blood clots are used at every stage of heart disease. Anti-clotting medications are generally classified as either antiplatelets or anticoagulants. Both antiplatelets and anticoagulants prevent blood clots from forming but they work in different ways:
All anti-clotting drugs increase the risk of bleeding, which can lead to dangerous situations, including stroke.
Appropriate anticlotting medications are started immediately in all patients. Such drugs are used with revascularization, and also as on-going maintenance to prevent a heart attack.
These drugs inhibit blood platelets from sticking together, and therefore help to prevent clots. Platelets are very small disc-shaped blood cells that are important for blood clotting. Antiplatelet drugs include:
Anticoagulants thin blood. They include:
All of these drugs pose a risk for bleeding.
Beta blockers reduce the oxygen demand of the heart by slowing the heart rate and lowering pressure in the arteries. They are effective for reducing deaths from heart disease. Beta blockers are usually given to patients early in their hospitalization, sometimes intravenously. Patients with heart failure or who are at risk of going into cardiogenic shock should not receive intravenous beta blockers. Long-term oral beta blocker therapy for patients with symptomatic coronary artery disease, particularly after heart attacks, is recommended in most patients.
These drugs include propranolol (Inderal), carvedilol (Coreg), bisoprolol (Zebeta), acebutolol (Sectral), atenolol (Tenormin), labetalol (Normodyne, Trandate), metoprolol (Lopressor, Toprol-XL), and esmolol (Brevibloc). All of these drugs are available in generic form. The FDA is currently reviewing the safety and effectiveness of some generic forms of extended-release metoprolol.
Administration During a Heart Attack
The beta blocker metoprolol may be given orally or through an IV within the first few hours of a heart attack to reduce damage to the heart muscle.
Prevention After a Heart Attack
Beta blocker pills are also used on a long-term basis (as maintenance therapy) after a first heart attack to help prevent future heart attacks.
Although usually well-tolerated, beta blocker side effects can include fatigue, lethargy, vivid dreams and nightmares, depression, memory loss, and dizziness. They can lower HDL (good) cholesterol. Beta blockers are categorized as non-selective or selective. Non-selective beta blockers, such as carvedilol and propranolol, can narrow bronchial airways. Patients with asthma, emphysema, or chronic bronchitis, may need to avoid non-selective beta blockers.
Patients should not abruptly stop taking these drugs. The sudden withdrawal of beta blockers can rapidly increase heart rate and blood pressure. The doctor may want the patient to slowly decrease the dose before stopping completely.
Anyone who has had a heart attack needs to take a statin drug to help lower cholesterol. After a heart attack, most people are asked to take more intensive doses.
The statin drugs approved in the United States are lovastatin (Mevacor, generic), pravastatin (Pravachol, generic), simvastatin (Zocor, generic), atorvastatin (Lipitor, generic), fluvastatin (Lescol), pitavastatin (Livalo), and rosuvastatin (Crestor).
Patients who cannot tolerate statin medications or those with very high cholesterol because of a genetic condition may be eligible for treatment with a special type of medication called PSK-9 inhibitors. Examples include alirocumab (Praluent) and evolocumab (Repatha).
Angiotensin Converting Enzyme Inhibitors
Angiotensin converting enzyme (ACE) inhibitors are important drugs for treating many patients who have had a heart attack, particularly for patients with and at risk for heart failure. ACE inhibitors should be given on the first day to such patients with a heart attack, unless there are medical reasons for not taking them.
Almost all patients admitted for ACS should receive ACE inhibitors if they have symptoms of heart failure or evidence of reduced left ventricular fraction on an echocardiogram. These drugs are also commonly used to treat high blood pressure (hypertension) and are recommended as first-line treatment for people with diabetes and kidney damage.
ACE inhibitors include captopril (Capoten), ramipril (Altace), enalapril (Vasotec), quinapril (Accupril), benazepril (Lotensin), perindopril (Aceon), and lisinopril (Prinivil, Zestril). All of these drugs are available in generic form.
Side effects of ACE inhibitors are uncommon but may include an irritating dry cough, excessive drops in blood pressure, and allergic reactions.
Calcium Channel Blockers
Calcium channel blockers may provide relief in patients with unstable angina whose symptoms DO NOT respond to nitrates and beta blockers, or for patients who are unable to take beta blockers, or for patients who are still hypertensive (have high blood pressure) despite other medications.
You can reduce your risk for a second heart attack by following secondary prevention measures. No one should be discharged from the hospital without these issues being addressed and appropriate medications prescribed. Lifestyle choices, particularly dietary factors, are equally important in preventing heart attacks.
Aim for a blood pressure of less than 140/90 mm Hg.
Everyone who has had a heart attack should receive a prescription for a statin drug before being discharged from the hospital. It is also important to control dietary cholesterol by reducing intake of saturated fats to less than 7% of total calories. Increased omega-3 fatty acid consumption (by eating more fish or taking fish oil supplements) can help reduce triglyceride levels.
A heart-healthy diet emphasizes vegetables, fruits, and whole grains. Include low-fat dairy products, poultry, fish, beans, olive oil, and nuts. Limit sweets and red meats. Some research suggests that increasing fiber consumption (from specifically grains and cereals) may help attack survivors live longer. Evidence indicates that food is the best source for heart-protective antioxidants and minerals; multivitamins DO NOT seems to have much benefit for secondary, or primary, prevention. (According to the United States Preventive Services Task Force, there is insufficient evidence that regular use multivitamin supplements helps prevent heart disease.)
Although the AHA recommends 150 minutes of moderate activity or 75 minutes of vigorous activity per week for most people, patients who already have cardiovascular disease should discuss an appropriate exercise regimen with their provider.
Exercise and diet are the foundations for weight management. Your body mass index (BMI) should be 18.5 to 24.8. Waist circumference is also an important measure of heart attack risk. Men's waist circumferences should be less than 40 inches (102 centimeters), while women's should be below 35 inches (89 centimeters). Guidelines recommend your doctor create an individualized weight loss plan for you if you are overweight or obese.
It is essential to stop smoking. Also, avoid exposure to secondhand smoke.
Most patients need to take low-dose aspirin (75 to 81 mg) on a regular daily basis after a heart attack. If you have had a drug-coated stent inserted, you must take another antiplatelet drug along with aspirin for at least 1 year following surgery. Most other patients will also have a year of dual antiplatelet therapy prescribed.
The American Heart Association (AHA) recommends that people who have heart disease should take daily low-dose aspirin (if told to by their doctor) for primary prevention of heart attack or stroke. The AHA also recommends aspirin as secondary prevention for people who have already had a heart attack or stroke. For these patients, the benefits of aspirin outweigh its risks, which include bleeding in the stomach and brain. People who DO NOT have current heart disease, high risk for heart disease, or a history of heart attack or stroke, should not take daily aspirin.
Your doctor may recommend that you take an ACE inhibitor or beta blocker drug on an ongoing basis. It is also important to have an annual influenza ("flu") vaccination.
Cardiac rehabilitation is extremely important after a heart attack. A cardiac rehabilitation program is coordinated by a multidisciplinary team that includes cardiologists, cardiac nurses, nutritional counselors, exercise physiologists, and others. The goal of cardiac rehabilitation is to help the patient regain physical strength, improve heart and overall health, and reduce the chances of having another heart attack.
Cardiac rehabilitation typically takes place on site, at a hospital-affiliated facility. Services may be offered as individual sessions or group classes, depending on the type of rehabilitation therapy.
Cardiac rehabilitation begins with a comprehensive evaluation and patient assessment, which includes a physical exam and exercise tolerance test. Your healthcare team will evaluate your physical and emotional health, and any lifestyle issues that may affect your ability to manage your health. Based on this information, the team will design an individualized rehabilitation plan for you.
A cardiac rehabilitation plan may include:
A supervised exercise program is an essential component of cardiac rehabilitation. Exercise therapy may include aerobic activity on a treadmill, stationary bike, rowing machine, or walking/jogging track, as well as strength training. Your cardiac rehab team will monitor your heart rate and rhythm, and gradually increase the intensity of your workout. You will also be given exercises to practice at home.
A nutritionist will review your eating habits and help you create dietary strategies that incorporate heart-healthy principles such as limiting saturated fats. The nutritionist may suggest following eating patterns such as the Mediterranean diet, which includes vegetables, fruits, fish, beans, nuts, and olive oil.
Exercise and diet are fundamental to weight control, but losing weight can be challenging for many patients. A cardiac rehab program may include a medically supervised weight loss program. Being overweight or obese significantly increases the risk for a future heart attack.
Coping with the physical, emotional, and lifestyle changes that follow a heart attack can be very stressful. Many cardiac rehabilitation programs offer instruction in relaxation techniques for stress management. Classes may include meditation, guided breathing, tai chi, yoga, or other forms of relaxation response.
Your program may offer educational classes and support groups on learning how to live and cope with heart disease.
Mental Health and Behavioral Counseling
Major depression occurs in many patients who have ACS or who have had heart attacks. Studies suggest that depression is a major predictor for increased mortality in both women and men. (One reason may be that depressed patients are less likely to comply with their heart medications.)
Guidelines recommend depression screening for all patients who have had a heart attack. Psychotherapeutic techniques, especially cognitive behavioral therapies, may be very helpful. For some patients, certain types of antidepressant drugs may be appropriate.
Behavioral therapies can assist with unhealthy habits such as smoking. Quitting smoking is one of the most important steps to take for rehabilitation and prevention.
Sexual activity can usually be safely resumed about a week after a heart attack, once a patient can engage in mild-to-moderate exercise without experiencing cardiac symptoms. Ease into sexual activity gradually, starting with low-exertion acts (fondling, kissing).
The American Heart Association recommends sexual counseling for all patients and their partners who have experienced a cardiac event such as a heart attack. Discuss with your doctor how your medications may affect your sexual function, and be sure to report to your doctor any heart symptoms you experience during sex.
2012 Writing Committee Members, Jneid H, Anderson JL, et al. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/Non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2012;126(7):875-910. PMID: 22800849 www.ncbi.nlm.nih.gov/pubmed/22800849.
Abraham NS, Hlatky MA, Antman EM, et al. ACCF/ACG/AHA 2010 Expert Consensus Document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. Circulation. 2010;122(24):2619-2633. PMID: 21060077 www.ncbi.nlm.nih.gov/pubmed/21060077.
American College of Emergency Physicians; Society for Cardiovascular Angiography and Interventions, O'Gara PT, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;61(4):e78-e140. PMID: 23256914 www.ncbi.nlm.nih.gov/pubmed/23256914.
Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC Guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol. 2014;64(24):e139-e228. PMID: 25260718 www.ncbi.nlm.nih.gov/pubmed/25260718.
Baber U, Mehran R, Sharma SK, et al. Impact of the everolimus-eluting stent on stent thrombosis: a meta-analysis of 13 randomized trials. J Am Coll Cardiol. 2011;58(15):1569-1577. PMID: 21924575 www.ncbi.nlm.nih.gov/pubmed/21924575.
Brilakis ES, Patel VG, Banerjee S. Medical management after coronary stent implantation: a review. JAMA. 2013;310(2):189-198. PMID: 23839753 www.ncbi.nlm.nih.gov/pubmed/23839753.
Eckel RH, Jakicic JM, Ard JD, et al. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. Circulation. 2014;129(25 Suppl 2):S76-S99. PMID: 24222015 www.ncbi.nlm.nih.gov/pubmed/24222015.
Fleg JL, Forman DE, Berra K, et al. Secondary prevention of atherosclerotic cardiovascular disease in older adults: a scientific statement from the American Heart Association. Circulation. 2013;128(22):2422-2446. PMID: 24166575 www.ncbi.nlm.nih.gov/pubmed/24166575.
Genest J, Libby P. Lipoprotein disorders and cardiovascular disease. In: Bonow RO, Mann DL, Zipes DP, Libby P, Bonow RO, Braunwald E, eds. Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine. 10th ed. Philadelphia, PA: Elsevier Saunders; 2015:chap 45.
Giugliano RP, Cannon CP, Braunwald E. Non ST-elevation acute coronary syndromes. In: Mann DL, Zipes DP, Libby P, Bonow RO, Braunwald E, eds. Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine. 10th ed. Philadelphia, PA: Elsevier Saunders; 2015:chap 53.
Hillis LD, Smith PK, Anderson JL, et al. 2011 ACCF/AHA guideline for coronary artery bypass graft surgery. A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Developed in collaboration with the American Association for Thoracic Surgery, Society of Cardiovascular Anesthesiologists, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2011;58(24):e123-e210. PMID: 22070836 www.ncbi.nlm.nih.gov/pubmed/22070836.
Jang JS, Spertus JA, Arnold SV, et al. Impact of multivessel revascularization on health status outcomes in patients with ST-segment elevation myocardial infarction and multivessel coronary artery disease. J Am Coll Cardiol. 2015;66(19):2104-2113. PMID: 26541921 www.ncbi.nlm.nih.gov/pubmed/26541921.
Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and The Obesity Society. J Am Coll Cardiol. 2014;129(25 Suppl 2):S102-S138. PMID: 24222017 www.ncbi.nlm.nih.gov/pubmed/24222017.
Jolly SS, Cairns JA, Yusuf S, et al. Outcomes after thrombus aspiration for ST elevation myocardial infarction: 1-year follow-up of the prospective randomised TOTAL trial. Lancet. 2016;387(10014):127-135. PMID: 26474811 www.ncbi.nlm.nih.gov/pubmed/26474811.
Kulik A, Ruel M, Jneid H, et al. Secondary prevention after coronary artery bypass graft surgery: a scientific statement from the American Heart Association. Circulation. 2015;131(10):927-964. PMID: 25679302 www.ncbi.nlm.nih.gov/pubmed/25679302.
Lamas GA, Boineau R, Goertz C, et al. Oral high-dose multivitamins and minerals after myocardial infarction: a randomized trial. Ann Intern Med. 2013;159(12):797-805. PMID: 24490264 www.ncbi.nlm.nih.gov/pubmed/24490264.
Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol. 2011;124(23):e574-e651. PMID: 22064601 www.ncbi.nlm.nih.gov/pubmed/22064601.
Lloyd-Jones DM, Hong Y, Labarthe D, et al. Defining and setting national goals for cardiovascular health promotion and disease reduction: The American Heart Association's strategic impact goal through 2020 and beyond. Circulation. 2010;121(4):586-613. PMID: 20089546 www.ncbi.nlm.nih.gov/pubmed/20089546.
Mega JL, Morrow DA. ST-elevation myocardial infarction. In: Mann DL, Zipes DP, Libby P, Bonow RO, Braunwald E, eds. Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine. 10th ed. Philadelphia, PA: Elsevier Saunders; 2015:chap 52.
Myerburg RJ, Castellanos A. Cardiac arrest and sudden cardiac death. In: Mann DL, Zipes DP, Libby P, Bonow RO, Braunwald E, eds. Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine. 10th ed. Philadelphia, PA: Elsevier Saunders; 2015:chap 39.
Newby LK, Jesse RL, Babb JD, et al. ACCF 2012 expert consensus document on practical clinical considerations in the interpretation of troponin elevations: a report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents. J Am Coll Cardiol. 2012;60(23):2427-2463. PMID: 23154053 www.ncbi.nlm.nih.gov/pubmed/23154053.
Schjerning Olsen AM, Fosbol EL, Lindhardsen J, et al. Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study. Circulation. 2011;123(20):2226-2235. PMID: 21555710 www.ncbi.nlm.nih.gov/pubmed/21555710.
Steinke EE, Jaarsma T, Barnason SA, et al. Sexual counseling for individuals with cardiovascular disease and their partners: a consensus document from the American Heart Association and the ESC Council on Cardiovascular Nursing and Allied Professions (CCNAP). Circulation. 2013;128(18):2075-2096. PMID: 23897867 www.ncbi.nlm.nih.gov/pubmed/23897867.
Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol. 2014;63(25 Pt B):2889-2934. PMID: 24239923 www.ncbi.nlm.nih.gov/pubmed/24239923.
Valgimigli M, Frigoli E, Leonardi S, et al. Bivalirudin or unfractionated heparin in acute coronary syndromes. N Engl J Med. 2015;373(11):997-1009. PMID: 26324049 www.ncbi.nlm.nih.gov/pubmed/26324049.
Vandvik PO, Lincoff AM, Gore JM, et al. Primary and secondary prevention of cardiovascular disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e637S-e668S. PMID: 22315274 www.ncbi.nlm.nih.gov/pubmed/22315274.
The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. A licensed medical professional should be consulted for diagnosis and treatment of any and all medical conditions. Links to other sites are provided for information only -- they do not constitute endorsements of those other sites. © 1997- A.D.A.M., a business unit of Ebix, Inc. Any duplication or distribution of the information contained herein is strictly prohibited.